Fig. 2

Renal risk in CV and renal outcomes trials with SGLT2 inhibitors. a Overall populations; b EMPA-REG OUTCOME, CANVAS program, DECLARE-TIMI 58, CREDENCE and DAPA-CKD baseline populations by eGFR group and median UACR. In DECLARE-TIMI 58, people with CrCl of ≤ 60 mL/min were excluded, which led to very few participants with eGFR at baseline < 60 mL/min/1.73 m². ^aDAPA-CKD T2D subpopulation only. VERTIS CV excluded from this figure because a median UACR was not reported [32]. CrCl creatinine clearance, CV cardiovascular, eGFR estimated glomerular filtration rate, SGLT2 sodium–glucose cotransporter 2, UACR urine albumin to creatinine ratio